STOCK TITAN

Agenus (NASDAQ: AGEN) pays Dr. Garo Armen salary in stock grant

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

ARMEN GARO H reported acquisition or exercise transactions in this Form 4 filing.

Agenus Inc. executive and director Dr. Garo H. Armen received 4,925 shares of Common Stock as stock-based salary for the pay period ending June 12, 2026. The shares were valued using the closing price of $3.30 on that date and are fully vested upon issuance under the Amended and Restated Agenus Inc. 2019 Equity Incentive plan. After this grant, Dr. Armen holds 360,892 shares directly, along with additional indirect holdings through IRA accounts and entities referenced in the footnotes.

Positive

  • None.

Negative

  • None.
Insider ARMEN GARO H
Role See Remarks
Type Security Shares Price Value
Grant/Award Common Stock 4,925 $3.30 $16K
holding Common Stock -- -- --
holding Common Stock -- -- --
Holdings After Transaction: Common Stock — 360,892 shares (Direct, null); Common Stock — 31,298 shares (Indirect, See Footnote)
Footnotes (1)
  1. At his request and with the approval of the Agenus Inc. Compensation Committee, Garo H. Armen's salary is being paid in stock, in lieu of cash. The amount reported herein represents the net amount of Dr. Armen's salary for the pay period ending June 12th, 2026. Such shares are issued in accordance with the Amended and Restated Agenus Inc. 2019 Equity Incentive are fully vested on the date of issuance. $3.30 is the closing price of our Common Stock on June 12th, 2026, the last trading day for the payroll date for the pay period ending June 12th, 2026. Shares are held in Dr. Armen's IRA accounts. Dr. Armen is trustee and has investment authority for the Garo Armen 2020 2 Year AG GRAT holder of 23,950 shares of our Common Stock. Dr. Armen is a general partner in Pixie Partners, a General Partnership ("Pixie"), which as of the date of this report owns 5,000 shares of our Common Stock. Dr. Armen has a pecuniary interest in only a portion of the shares held by Pixie and disclaims beneficial ownership to the extent of his pecuniary interest therein.
Stock salary grant 4,925 shares Common Stock granted as salary for pay period ending June 12, 2026
Grant valuation price $3.30 per share Closing price on June 12, 2026 used for stock salary
Direct holdings after grant 360,892 shares Common Stock directly owned by Dr. Armen after the transaction
IRA holdings 28,950 shares Common Stock held in Dr. Armen’s IRA accounts as reported
Additional indirect holdings 31,298 shares Common Stock held indirectly with nature of ownership per footnote
GRAT holdings 23,950 shares Common Stock held by Garo Armen 2020 2 Year AG GRAT
Pixie Partners holdings 5,000 shares Common Stock owned by Pixie Partners; Armen has partial pecuniary interest
Equity Incentive financial
"issued in accordance with the Amended and Restated Agenus Inc. 2019 Equity Incentive"
Equity incentive is a form of pay that gives employees or executives a stake in the company through stock or the right to buy stock, often granted with conditions that spread out over time. It matters to investors because it aligns workers’ interests with shareholders—encouraging growth and retention—but can also affect share count and profits when new shares are issued, similar to giving team members a slice of the company pie that can grow or dilute others’ slices.
Compensation Committee financial
"with the approval of the Agenus Inc. Compensation Committee, Garo H. Armen's salary is being paid"
A compensation committee is a group within a company's leadership responsible for setting and reviewing how much top executives and employees are paid, including salaries, bonuses, and benefits. It matters to investors because fair and effective pay decisions can influence a company's performance, leadership motivation, and overall governance, helping ensure that the company’s management is aligned with shareholders’ interests.
IRA accounts financial
"Shares are held in Dr. Armen's IRA accounts."
An IRA account is a tax-advantaged personal savings account designed to help people invest for retirement; think of it as a special piggy bank that gives you tax breaks to encourage long-term saving. Different IRA types change when you pay taxes and when you can take money out, so they matter to investors because the choice affects your after-tax returns, portfolio decisions, and the timing of withdrawals during retirement.
GRAT financial
"Garo Armen 2020 2 Year AG GRAT holder of 23,950 shares of our Common Stock."
pecuniary interest financial
"Dr. Armen has a pecuniary interest in only a portion of the shares held by Pixie"
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
ARMEN GARO H

(Last)(First)(Middle)
C/O AGENUS INC.
3 FORBES ROAD

(Street)
LEXINGTON MASSACHUSETTS 02421

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
AGENUS INC [ AGEN ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
XOfficer (give title below)Other (specify below)
See Remarks
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/12/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock(1)06/12/2026A4,925A$3.3(2)360,892D
Common Stock31,298ISee Footnote(3)
Common Stock28,950ISee Footnote(4)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. At his request and with the approval of the Agenus Inc. Compensation Committee, Garo H. Armen's salary is being paid in stock, in lieu of cash. The amount reported herein represents the net amount of Dr. Armen's salary for the pay period ending June 12th, 2026. Such shares are issued in accordance with the Amended and Restated Agenus Inc. 2019 Equity Incentive are fully vested on the date of issuance.
2. $3.30 is the closing price of our Common Stock on June 12th, 2026, the last trading day for the payroll date for the pay period ending June 12th, 2026.
3. Shares are held in Dr. Armen's IRA accounts.
4. Dr. Armen is trustee and has investment authority for the Garo Armen 2020 2 Year AG GRAT holder of 23,950 shares of our Common Stock. Dr. Armen is a general partner in Pixie Partners, a General Partnership ("Pixie"), which as of the date of this report owns 5,000 shares of our Common Stock. Dr. Armen has a pecuniary interest in only a portion of the shares held by Pixie and disclaims beneficial ownership to the extent of his pecuniary interest therein.
Remarks:
Chairman, Chief Executive Officer and Principal Financial Officer
/s/ Melissa Orilall, as Attorney-in-Fact for Garo H. Armen06/12/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Agenus (AGEN) report about Dr. Garo Armen’s latest share grant?

Agenus reported that Dr. Garo H. Armen received 4,925 shares of Common Stock as stock-based salary for the pay period ending June 12, 2026. These shares are fully vested on issuance under the company’s 2019 Equity Incentive plan.

At what price was Dr. Armen’s Agenus (AGEN) stock-based salary calculated?

Dr. Armen’s stock-based salary was calculated using $3.30 per share, the closing price of Agenus Common Stock on June 12, 2026. This closing price was the last trading day for the relevant payroll date in the reported pay period.

How many Agenus (AGEN) shares does Dr. Garo Armen hold directly after this Form 4?

Following the reported stock grant, Dr. Garo H. Armen directly holds 360,892 shares of Agenus Common Stock. This figure reflects his direct ownership position after receiving 4,925 fully vested shares as salary in stock instead of cash compensation.

How is Dr. Armen’s salary being paid according to the Agenus (AGEN) filing?

At Dr. Armen’s request and with Compensation Committee approval, his salary is being paid in stock instead of cash. The 4,925 shares reported represent the net amount of salary for the pay period ending June 12, 2026, issued fully vested.

Is Dr. Armen’s Form 4 transaction an open-market purchase of Agenus (AGEN) stock?

No, the transaction is a stock-based salary grant, not an open-market purchase. The Form 4 describes a compensation-related acquisition of 4,925 fully vested shares issued under Agenus’s 2019 Equity Incentive plan in lieu of paying salary in cash.